Literature DB >> 19076726

In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression.

Akio Ohta1, J Kjaergaard, S Sharma, M Mohsin, N Goel, M Madasu, E Fradkov, Akiko Ohta, M Sitkovsky.   

Abstract

BACKGROUND AND
PURPOSE: The increased levels of extracellular adenosine in inflamed tissues down-regulate activated immune cells via the A(2A) adenosine receptor. This A(2A) adenosine receptor-mediated immunosuppression is a disqualifying obstacle in cancer immunotherapy as it protects cancerous tissues from adoptively transferred anti-tumour T cells. The aim of this study was to test whether the negative selection of T cells will produce T cells that are resistant to inhibition by extracellular adenosine. EXPERIMENTAL APPROACH: Cytotoxic T lymphocytes (CTL) were developed by mixed lymphocyte culture in the presence or absence of the adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA). The sensitivity of CTL to adenosine analogues was characterized by cAMP induction, interferon-gamma production and cytotoxicity. KEY
RESULTS: CTL that could proliferate even in the presence of NECA were less susceptible to inhibition by A(2A) adenosine receptor agonists, as shown by a much smaller accumulation of cAMP and less inhibition of interferon-gamma production compared with control CTL. The successful protocol to produce CTL that are both resistant to adenosine-mediated immunosuppression and maintain strong cytotoxicity and interferon-gamma secretion required NECA to be added only during the expansion stage after the establishment of CTL. In contrast, the priming of resting T cells in the presence of NECA resulted in T cells with impaired effector functions. CONCLUSIONS AND IMPLICATIONS: Adenosine-resistant effector T cells were successfully obtained by exposure of activated T cells to NECA. These in vitro studies form the basis for future attempts to produce anti-tumour T cells that are more effective in adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076726      PMCID: PMC2697837          DOI: 10.1111/j.1476-5381.2008.00019.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells.

Authors:  M Koshiba; H Kojima; S Huang; S Apasov; M V Sitkovsky
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

Review 2.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

3.  Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

4.  Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport.

Authors:  S Kobayashi; H Zimmermann; D E Millhorn
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

5.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

6.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Authors:  L Gorelik; R A Flavell
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

7.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.

Authors:  S Huang; S Apasov; M Koshiba; M Sitkovsky
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

8.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

9.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

10.  Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor.

Authors:  T Vang; K M Torgersen; V Sundvold; M Saxena; F O Levy; B S Skålhegg; V Hansson; T Mustelin; K Taskén
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  17 in total

1.  Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold.

Authors:  T Santhosh Kumar; Shilpi Mishra; Francesca Deflorian; Lena S Yoo; Khai Phan; Miklos Kecskés; Angela Szabo; Bidhan Shinkre; Zhan-Guo Gao; William Trenkle; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2010-11-21       Impact factor: 2.823

2.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

Review 3.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

4.  Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Authors:  Anke C Schiedel; Svenja K Lacher; Carsten Linnemann; Percy A Knolle; Christa E Müller
Journal:  Purinergic Signal       Date:  2013-01-29       Impact factor: 3.765

Review 5.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

6.  Extracellular adenosine controls NKT-cell-dependent hepatitis induction.

Authors:  Meenakshi Subramanian; Radhika Kini; Manasa Madasu; Akiko Ohta; Michael Nowak; Mark Exley; Michail Sitkovsky; Akio Ohta
Journal:  Eur J Immunol       Date:  2014-02-19       Impact factor: 5.532

7.  Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible.

Authors:  Akio Ohta; Manasa Madasu; Meenakshi Subramanian; Radhika Kini; Graham Jones; Alexander Choukèr; Akiko Ohta; Michail Sitkovsky
Journal:  Int Immunol       Date:  2013-10-22       Impact factor: 4.823

8.  Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes.

Authors:  Yunyun Su; Edwin K Jackson; Elieser Gorelik
Journal:  Cancer Immunol Immunother       Date:  2010-10-20       Impact factor: 6.968

Review 9.  Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.

Authors:  Michail Sitkovsky; Akio Ohta
Journal:  J Mol Med (Berl)       Date:  2013-01-20       Impact factor: 4.599

Review 10.  Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy.

Authors:  Stephen M Hatfield; Michail V Sitkovsky
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.